IntoCell, Inc. (KOSDAQ:287840)

South Korea · Delayed Price · Currency is KRW

50,800

+100 (0.20%)

At close: Feb 27, 2026

36.93% (1Y)

Market Cap	705.56B
Revenue (ttm)	1.68B
Net Income (ttm)	-10.45B
Shares Out	15.01M
EPS (ttm)	-754.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,861
Average Volume	133,936
Open	50,300
Previous Close	50,700
Day's Range	49,600 - 51,400
52-Week Range	21,400 - 74,900
Beta	n/a
RSI	39.13
Earnings Date	n/a

About IntoCell

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxi... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 287840

Full Company Profile

Financial Performance

In 2024, IntoCell's revenue was 2.91 billion, an increase of 79.72% compared to the previous year's 1.62 billion. Losses were -9.91 billion, -40.91% less than in 2023.

Financial Statements

News

There is no news available yet.